{"entity":{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","aka":[],"tldr":"Seattle oncologist who led STAMP, the trial that showed pembrolizumab after surgery reduces recurrence of Merkel cell carcinoma, a rare and aggressive skin cancer.","summary":"Shailender Bhatia is a medical oncologist at Fred Hutchinson Cancer Center and the University of Washington who focuses on Merkel cell carcinoma and melanoma. He was the study chair and first author of the 2025 New England Journal of Medicine report of the ECOG-ACRIN EA6174 STAMP trial, in which adjuvant pembrolizumab improved recurrence-free survival compared with observation after resection of stage I to III Merkel cell carcinoma.","asOf":"2026-09-18","links":[],"tags":["skin","immunotherapy","trialist"],"related":[],"cancers":["merkel-cell-carcinoma","skin-cancer","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":["stamp-merkel"],"people":[],"bottlenecks":[],"keyPapers":["paper-shailender-bhatia-cell-2017","paper-checkmate-238-nejm-2017","paper-keynote-017-n-engl-j-med-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Fred Hutchinson Cancer Center and University of Washington","institutionId":"fred-hutch","specialisms":["Merkel cell carcinoma","Melanoma","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bhatia%5BAuthor%5D"}],"papers":[{"title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","journal":"Cell","year":2017,"url":"https://doi.org/10.1016/j.cell.2017.09.028","doi":"10.1016/j.cell.2017.09.028","note":"Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 1984 citations on Europe PMC."},{"title":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1709030","doi":"10.1056/NEJMoa1709030","note":"Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 1713 citations on Europe PMC."},{"title":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/nejmoa1603702","doi":"10.1056/nejmoa1603702","note":"Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 950 citations on Europe PMC."}],"orcid":"0000-0002-3816-2238"},"route":"/people/shailender-bhatia/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"}],"trial":[{"id":"stamp-merkel","kind":"trial","name":"STAMP (EA6174)","route":"/trials/stamp-merkel/"}],"paper":[{"id":"paper-checkmate-238-nejm-2017","kind":"paper","name":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","route":"/key-papers/paper-checkmate-238-nejm-2017/"},{"id":"paper-keynote-017-n-engl-j-med-2016","kind":"paper","name":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","route":"/key-papers/paper-keynote-017-n-engl-j-med-2016/"},{"id":"paper-shailender-bhatia-cell-2017","kind":"paper","name":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","route":"/key-papers/paper-shailender-bhatia-cell-2017/"}]}}